Jo Ann Horowitz

1.3k total citations
15 papers, 958 citations indexed

About

Jo Ann Horowitz is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Genetics. According to data from OpenAlex, Jo Ann Horowitz has authored 15 papers receiving a total of 958 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Genetics. Recurrent topics in Jo Ann Horowitz's work include Radiopharmaceutical Chemistry and Applications (6 papers), Virus-based gene therapy research (5 papers) and Cancer Research and Treatments (5 papers). Jo Ann Horowitz is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (6 papers), Virus-based gene therapy research (5 papers) and Cancer Research and Treatments (5 papers). Jo Ann Horowitz collaborates with scholars based in United States, Germany and Switzerland. Jo Ann Horowitz's co-authors include Thomas C. Hall, David M. Goldenberg, H Goldenberg, Robert M. Sharkey, J A Siegel, Mary Ann Fritz, R. Kreienberg, Beth Y. Karlan, Richard E. Buller and Ingo B. Runnebaum and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Human Gene Therapy.

In The Last Decade

Jo Ann Horowitz

15 papers receiving 920 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jo Ann Horowitz United States 12 410 364 359 332 203 15 958
RE Hawkins United Kingdom 14 192 0.5× 373 1.0× 220 0.6× 226 0.7× 40 0.2× 29 700
J Schlom United States 19 564 1.4× 661 1.8× 908 2.5× 103 0.3× 106 0.5× 38 1.6k
C S Woodhouse United States 16 343 0.8× 392 1.1× 584 1.6× 92 0.3× 57 0.3× 23 1.0k
Curiel Dt United States 8 414 1.0× 409 1.1× 56 0.2× 190 0.6× 120 0.6× 8 726
Daniel R. Vlock United States 17 447 1.1× 332 0.9× 153 0.4× 62 0.2× 50 0.2× 32 916
Carter T. Fields United States 9 811 2.0× 483 1.3× 517 1.4× 403 1.2× 20 0.1× 17 1.4k
Jerry L. Klein United States 20 265 0.6× 347 1.0× 528 1.5× 31 0.1× 60 0.3× 42 1.2k
Murray Stackhouse United States 15 371 0.9× 367 1.0× 96 0.3× 90 0.3× 57 0.3× 24 722
Birgit C. Schultes United States 19 334 0.8× 393 1.1× 405 1.1× 42 0.1× 48 0.2× 53 1.1k
Jonathan Treisman United States 14 675 1.6× 425 1.2× 147 0.4× 243 0.7× 35 0.2× 31 1.1k

Countries citing papers authored by Jo Ann Horowitz

Since Specialization
Citations

This map shows the geographic impact of Jo Ann Horowitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jo Ann Horowitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jo Ann Horowitz more than expected).

Fields of papers citing papers by Jo Ann Horowitz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jo Ann Horowitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jo Ann Horowitz. The network helps show where Jo Ann Horowitz may publish in the future.

Co-authorship network of co-authors of Jo Ann Horowitz

This figure shows the co-authorship network connecting the top 25 collaborators of Jo Ann Horowitz. A scholar is included among the top collaborators of Jo Ann Horowitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jo Ann Horowitz. Jo Ann Horowitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Thomas, B M, Scott H. Kaufmann, Jacqueline M. Greer, et al.. (2011). Phase I Dose-Escalation Study of SCH 900776 in Combination with Cytarabine (Ara-C) in Patients with Acute Leukemia. Blood. 118(21). 1531–1531. 4 indexed citations
2.
Daud, Adil, Gregory M. Springett, David S. Mendelson, et al.. (2010). 494 A phase I trial of SCH900776, a selective inhibitor of checkpoint kinase CHK-1, in combination with Gemcitabine in advanced solid tumors. European Journal of Cancer Supplements. 8(7). 158–158. 2 indexed citations
3.
Gilbert, Mark R., C. Conrad, Howard Colman, et al.. (2006). A phase I study of temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), lonafarnib (Sarazar, SCH66336) in recurrent glioblastoma. Journal of Clinical Oncology. 24(18_suppl). 1556–1556. 25 indexed citations
4.
Atencio, Isabella, Michael J. Grace, Mary Ann Fritz, et al.. (2005). Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial. Cancer Gene Therapy. 13(2). 169–181. 40 indexed citations
5.
Buller, Richard E., Ingo B. Runnebaum, Beth Y. Karlan, et al.. (2002). A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Therapy. 9(7). 553–566. 138 indexed citations
6.
Buller, Richard E., Mark S. Shahin, Jo Ann Horowitz, et al.. (2002). Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. Cancer Gene Therapy. 9(7). 567–572. 53 indexed citations
7.
Schüler, Martin, Richard Herrmann, Jacques De Grève, et al.. (2001). Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients Receiving Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results of a Multicenter Phase II Study. Journal of Clinical Oncology. 19(6). 1750–1758. 145 indexed citations
8.
9.
Schüler, Martin, Christoph Rochlitz, Jo Ann Horowitz, et al.. (1998). A Phase I Study of Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients with Advanced Non-Small Cell Lung Cancer. Human Gene Therapy. 9(14). 2075–2082. 123 indexed citations
10.
Goldenberg, David M., Jo Ann Horowitz, Robert M. Sharkey, et al.. (1991). Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody.. Journal of Clinical Oncology. 9(4). 548–564. 171 indexed citations
11.
Goldenberg, David M., H Goldenberg, Robert M. Sharkey, et al.. (1990). In-vivo antibody imaging for the detection of human tumors. Cancer treatment and research. 51. 273–292. 7 indexed citations
12.
Goldenberg, David M., H Goldenberg, R M Sharkey, et al.. (1990). Clinical studies of cancer radioimmunodetection with carcinoembryonic antigen monoclonal antibody fragments labeled with 123I or 99mTc.. PubMed. 50(3 Suppl). 909s–921s. 56 indexed citations
13.
Siegel, J A, et al.. (1990). Tumor, red marrow, and organ dosimetry for 131I-labeled anti-carcinoembryonic antigen monoclonal antibody.. PubMed. 50(3 Suppl). 1039s–1042s. 51 indexed citations
14.
Goldenberg, David M., H Goldenberg, R M Sharkey, et al.. (1989). Imaging of colorectal carcinoma with radiolabeled antibodies. Seminars in Nuclear Medicine. 19(4). 262–281. 63 indexed citations
15.
Siegel, Jeffry A., et al.. (1989). Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. International Journal of Radiation Applications and Instrumentation Part B Nuclear Medicine and Biology. 16(6). 553–559. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by RE Hawkins Breakdown of academic impact, for papers by J Schlom Breakdown of academic impact, for papers by C S Woodhouse Breakdown of academic impact, for papers by Curiel Dt Breakdown of academic impact, for papers by Daniel R. Vlock Breakdown of academic impact, for papers by Carter T. Fields Breakdown of academic impact, for papers by Jerry L. Klein Breakdown of academic impact, for papers by Murray Stackhouse Breakdown of academic impact, for papers by Birgit C. Schultes Breakdown of academic impact, for papers by Jonathan Treisman
Rankless by CCL
2026